Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide in Fludarabine-Refractory or Relapsed CLL
NCT00006090Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2000
- Primary completion
- Oct 2001
- Modality
- DNA Intercalators/Alkylators
01
Overview
A Phase 2 trial of arsenic trioxide in chronic lymphocytic leukemia (CLL), sponsored by University of Texas MD Anderson Cancer Center. Planned start Jun 2000; status: withdrawn.
02
Drugs
arsenic trioxide
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00006090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006090.